文章核心观点 - 辉瑞公司正在努力进入由Ozempic和Wegovy等GLP-1药物主导的减肥治疗领域[1][2] - 辉瑞之前的GLP-1候选药物lotiglipron和danuglipron均因安全性问题而被迫停止临床试验[3][4] - 辉瑞CEO表示公司正在研发3种减肥药物,包括2种GLP-1机制和1种非GLP-1机制的药物[5][6] - 辉瑞股价呈现下降三角形走势,面临一些下行压力[7] 公司业务表现 - 辉瑞正在努力从COVID-19疫苗和治疗药物收入下降的影响中恢复[9][10] - 公司Q1 2024财报显示收入同比下降19.5%,但非COVID-19业务收入增长11%[10] - 公司预计2024年全年收入将达585亿美元至615亿美元,调整后每股收益为2.15美元至2.35美元[11] - 公司CEO对非COVID-19业务表现持乐观态度,多个主要产品线如Eliquis、Prevnar和Vyndaqel等实现了良好增长[12][13] 行业竞争格局 - 除了Novo Nordisk和Eli Lilly,辉瑞还面临来自Viking Therapeutics、Altimmune和Structure Therapeutics等其他GLP-1药物开发商的竞争[2] - 辉瑞之前的GLP-1候选药物lotiglipron和danuglipron均因安全性问题而被迫停止临床试验,未能成为有力的竞争对手[3][4] - 辉瑞正在研发新的减肥药物,希望能在这一领域分一杯羹[5][6]

Pfizer's valuation looks attractive, but that doesn't mean the stock is a lock to outperform the broader market.Pfizer (PFE 0.86%) can be a polarizing stock to own right now. Its future remains hazy given that it is facing some troubling patent cliffs and revenue from its COVID-19 vaccine is dwindling. But at the same time, the shares look cheap, and they could possess a lot of upside in the long run. Investors, however, aren't exactly loading up on the stock. Year to date, it's down around 3%.The shares' t ...

文章核心观点 - 公司在过去三年因新冠疫情相关药品销售而获得大量收入,但随着疫情影响减弱,这些收入正在大幅下降 [6][7] - 公司的主要业务分为三大板块:Primary Care、Specialty Care和Oncology,其中Oncology板块表现最为亮眼,收入增长18.4% [7][8][9] - 公司预计2024财年收入将保持平稳,但利润将实现17%-28%的增长 [10][11] - 公司近期完成了430亿美元收购Seagen的交易,这将为公司的肿瘤业务带来新的增长动力 [14] 公司概况 - 公司成立于1849年,是全球最大的制药公司之一,拥有约88,000名员工,年收入约600亿美元 [3] - 公司主要从事药品和疫苗的研发生产,涉及免疫学、肿瘤学、心血管和神经学等领域 [3][4] 财务表现 - 2023年第一季度,公司总收入同比下降21%,经营利润和每股收益也分别下降43.7%和43.3% [5] - 收入下滑主要是由于新冠相关药品销售大幅下降,但剔除这些因素,公司核心业务仍保持增长 [7] - 公司预计2024财年收入将保持平稳,利润将实现17%-28%的增长 [10][11] - 公司近期完成了430亿美元收购Seagen,这将为公司的肿瘤业务带来新的增长动力 [14] 风险因素 - 公司主要收入来自非肿瘤业务,如果这些业务无法实现增长,将影响公司整体业绩 [17] - 未来两年内,公司将有多个重要产品专利到期,面临专利悬崖风险 [18] - 公司目前的股息支付率较高,可能存在安全性隐忧 [20] 估值分析 - 基于过去10年的平均自由现金流,公司的内在价值约为37.61美元,低于当前股价,存在一定投资价值 [25] - 公司股价目前处于近10年低位,估值水平较低,但未来增长动力存在一定不确定性 [23]

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing approval for their Omicron JN.1-adapted monovalent COVID-19 vaccine.The CHMP has recommended the approval of Comirnaty JN.1, the Omicron JN.1-adapted monovalent COVID-19 vaccine, for active immunization against the COVID-19 virus in individuals aged six months and above.The decision was based on the recommendation from the World Health ...

In this articlePFEKena Betancur | Corbis News | Getty ImagesPfizer had a "phenomenal" first quarter — and Wall Street took notice, CEO Albert Bourla told thousands of employees during a companywide town hall on May 2, according to a recording heard by CNBC. A day earlier, the pharmaceutical giant's stock had closed 6% higher after its quarterly results topped analyst estimates and it hiked its full-year outlook. It was a far cry from the year prior, when Pfizer's shares plunged more than 40%, making it one ...

These top healthcare stocks are no-brainer buys in 2024 and beyond.This latest bull market is seeing a wave of enthusiasm from investors ... for the stocks of select companies. While some stocks are getting enthusiastic buy-in, there are plenty of others that haven't quite joined in on the market frenzy.When you're investing in stocks with a long-term mindset around a quality company's ability to execute a business plan, you can afford to be patient and eventually benefit from the growth stories it generate ...

One of the pharma giant's top-selling products is about to face some intense competition.It's no secret why Pfizer (PFE -0.82%) stock has been struggling this year. Investors are worried about how well the company will be able to do in light of waning demand for its COVID-19 vaccine and pill. It's also facing patent cliffs for many of its top drugs. That's why even though it's trading at a seemingly cheap 12 times its estimated future earnings, investors aren't piling into the stock. And now, one of its riv ...

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and olderRecommendation is based on pre-clinical and epidemiological data showing that the JN.1-adapted monovalent COVID-19 vaccine generates an improved immune response against multiple JN.1 sublineagesDoses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission NEW YORK and MAINZ, Germany, June 27, 2024 — Pfizer Inc. ( ...

One company's negative results can increase scrutiny of another's work.When one player stumbles in a high-stakes competition, it's often to the glee of the other contenders. In mid-June, Pfizer's (PFE -0.86%) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd be logical to assume that shares of Sarepta Therapeutics, (SRPT -1.64%) a biotech focused on developing DMD drugs, would then rise.But that didn't happen -- at least not until Sare ...

Pfizer (PFE) closed the latest trading day at $27.99, indicating a -1.3% change from the previous session's end. The stock fell short of the S&P 500, which registered a gain of 0.09% for the day. Meanwhile, the Dow lost 0.1%, and the Nasdaq, a tech-heavy index, added 0.16%.Prior to today's trading, shares of the drugmaker had lost 1.8% over the past month. This has lagged the Medical sector's gain of 2.3% and the S&P 500's gain of 2.83% in that time.The investment community will be closely monitoring the pe ...